HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

NCT00196651 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: IL-2
BIOLOGICAL: LIPO-6T
BIOLOGICAL: ALVAC VIH 1433

Sponsor

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators

[object Object]